A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.

Hartmut DöhnerCarsten Müller-TidowMichael LübbertWalter FiedlerAlwin KrämerJörg WestermannGesine BugRichard F SchlenkUtz KrugRainer-Georg GoeldnerJames HilbertTillmann TaubeOliver Gerhard Ottmann

Published in: British journal of haematology (2018)

Keyphrases

acute myeloid leukemia
phase iii
study protocol
high dose
phase ii
clinical trial
bone marrow
dendritic cells
low dose
double blind